Zentek Ltd.
ZTEKF Healthcare Medical Instruments & Supplies
Zentek Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $120,200.00, down 80.8% from fiscal 2025. In the quarter to June 2026, revenue fell 95.4%, EPS was flat, free cash flow fell 254.6% and total debt rose 6.53%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow ZTEKF
Zentek Ltd. (ZTEKF) EV/Sales
As of 16 October 2026, Zentek Ltd. (ZTEKF) trades at a EV/Sales of 288×. Over the past ten years it has ranged from −739× (June 2023) to 4,405× (November 2024); the current reading is higher than 76% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 472× | 158.17% |
| FY2025 | 183× | (95.68%) |
| FY2024 | 4,233× | — |
| FY2023 | −662× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 472× | 300.77% |
| Dec 2025 | 118× | (4.57%) |
| Sep 2025 | 123× | (27.67%) |
| Jun 2025 | 171× | (6.67%) |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DXR Daxor Corporation compare | −14.4× |
| MBOT Microbot Medical Inc. compare | −2.9× |
| NYXH Nyxoah SA compare | 0.7× |
| POCI Precision Optics Corp. compare | 0.9× |
| HBIO Harvard Bioscience, Inc. compare | 1.1× |
| NEPH Nephros Inc. compare | 1.7× |
| MLSS Milestone Scientific, Inc. compare | 3.1× |
| STXS Stereotaxis Inc. compare | 3.1× |
| ZTEKF Zentek Ltd. | 288× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)